Thrombocytopenia caused by the development of antibodies to thrombopoietin

Blood

Volumn 98, Issue 12, 2001, Pages 3241-3248

  Li, Junzhi ^a,b,c   Yang, Chun ^a,b,c   Xia, Yuping ^a,b,c   Bertino, Amy ^a,b,c   Glaspy, John ^a,b,c   Roberts, Michael ^a,b,c   Kuter, David J ^a,b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Pediatric Hematology and Oncology   (United States)

^d Massach usetts General Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYCLOSPORIN; EPITOPE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; PREDNISONE; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BONE MARROW EXAMINATION; CASE REPORT; CONTROLLED STUDY; CROSS REACTION; FEMALE; HUMAN; HUMAN CELL; MEGAKARYOCYTE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0035760892     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.12.3241     Document Type: Article

References (33)

1. Kaushansky K. Thrombopoietin. N Engl J Med. 1998;339:746-754.
2. Yang C, Li YC, Kuter DJ. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol. 1999;105:478-485.
3. de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 1996;183:651-656.
4. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science. 1994;265:1445-1447.
5. Carver-Moore K, Broxmeyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood. 1996;88:803-808.
6. Kuter DJ. Future directions with platelet growth factors. Semin Hematol. 2000;37:41-49.
7. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364-368.
8. Schiffer CA, Miller K, Larson RA, et al. A doubleblind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95:2530-2535.
9. Harker LA, Carter RA, Marzec UM, et al. Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy. Blood. 1998;92(suppl 1):707a.
10. Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in normal platelet donors. Blood. 2001;98:1339-1345.
11. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118-3128.
12. Tomita D, Petrarca M, Paine T, Olson K, Roskos L, Cheung E. Effect of a single dose of pegylated human recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet counts: implications for platelet apheresis. Transfusion. 1997;37:2S.
13. Crawford J, Glaspy J, Belani C, et al. A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-HUMGDF) with filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy. Proc Am Soc Clin Oncol. 1998;17:73a.
14. Li J, Xia Y, Kuter D. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacodynamics. BrJ Haematol. 1999;106:345-356.
15. Li J, Sabath DF, Kuter DJ. Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets. Cytokine. 2000;12:835-844.
16. Bussel J, Aledort L, Hayward C, et al. A prospective cross-sectional study to characterize selected autoimmune (AI) markers and report the incidence of antithrombopoietin antibodies in patients wtih immune thrombocytopenic purpura. Blood. 2000;96:250a.
17. Li J, Xia Y, Bertino A, Coburn J, Kuter DJ. Characterization of an anti-thrombopoietin antibody that developed in a cancer patient following the injection of PEG-rHuMGDF. Blood. 1999;94:51a.
18. Nichol JL. Thrombopoietin levels after chemotherapy and in naturally occurring human diseases. Curr Opin Hematol. 1998;5:203-208.
19. van Den Brink EN, Turenhout EA, Davies J, et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood. 2000;95:558-563.
20. Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines-friends or foes? Immunol Today. 1990;11:167-169.
21. Ragnhammar P, Friesen HJ, Frodin JE, et al. Induction of anti-recombinant human granulocytemacrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood. 1994;84:4078-4087.
22. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997;126:673-681.
23. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994;91:11104-11108.
24. Erslev AJ. Erythropoietin titers in health and disease. Semin Hematol. 1991;28:2-8.
25. Linardaki GD, Boki KA, Fertakis A, Tzioufas AG. Pure red cell aplasia as presentation of systemic lupus erythematosus: antibodies to erythropoietin. Scand J Rheumatol. 1999;28:189-191.
26. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure redcell aplasia. N Engl J Med. 1996;334:630-633.
27. Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med. 1996;335:523-524.
28. Laricchia-Robbio L, Moscato S, Genua A, Liberati AM, Revoltella RP. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J Cell Physiol. 1997;173:219-226.
29. Abina MA, Tulliez M, Duffour MT, et al. Thrombopoietin (TPO) knockout phenotype induced by cross-reactive antibodies against TPO following injection of mice with recombinant adenovirus encoding human TPO. J Immunol. 1998;160:4481-4489.
30. Dale DC, Nichol JL, Rich DA, et al. Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand. Blood. 1997;90:3456-3461.
31. Shiozaki H, Miyawaki S, Kuwaki T, Hagiwara T, Kato T, Miyazaki H. Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood. 2000;95:2187-2188.
32. Hill W, Landgraf R. Successful treatment of amegakaryocytic thrombocytopenic purpura with cyclosporine. N Engl J Med. 1985;312:1060-1061.
33. Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A. 1999;96:3132-3136.